Clearmind Medicine (CMND) received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder. This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company’s clinical trial, of which the first cohort treatment was successfully completed. The trial includes other institutions, such as Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine and Tel Aviv Sourasky Medical Center, Israel. The study at Hadassah-University Medical Center will be led by Prof. Joseph Caraco, Director of Clinical Pharmacology Unit in the Department of Medicine.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind announces notice of publication of patent for MEAI in China
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Psychedelic: Compass Pathways, GH Research report Q3 earnings
- Clearmind Medicine files patent application in South Korea
- Clearmind Medicine announces publication of U.S. patent application